Baird raised the firm’s price target on Apellis to $105 from $90 and keeps an Outperform rating on the shares. The analyst is incrementally positive on broad label for Syfovre in GA (geographic atrophy) and believes the label is the best case scenario with its broad indication, flexible dosing, and strong 24-month data.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
- Apellis price target raised to $91 from $86 at Citi
- Apellis rally on approval ‘might fade,’ says Wells Fargo
- Iveric now has ‘clearer path towards approval,’ says BofA
- FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness